Association between ruptured membranes, tocolytic therapy, and respiratory distress syndrome.
Two hundred ninety-seven patients from the placebo group of the National Institutes of Health Collaborative Study on Antenatal Steroid Therapy for prevention of respiratory distress syndrome were selected for analysis to investigate a possible association between premature rupture of the membranes, tocolytic therapy, and respiratory distress syndrome. Both premature rupture of the membranes and tocolytic therapy with isoxsuprine were individually associated with a lowered incidence of respiratory distress syndrome. However, when present together, their protective effect was not additive and resulted in a higher incidence of respiratory distress syndrome. It is suggested that the use of tocolytic therapy with beta-adrenergic agents be restricted to patients with intact membranes.
D000653:Amniotic Fluid / Q000032:analysis; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000150:complications*; D006801:Humans; D007231:Infant, Newborn; D007556:Isoxsuprine / Q000009:adverse effects / Q000627:therapeutic use*; D007752:Obstetric Labor, Premature / Q000517:prevention & control*; D010713:Phosphatidylcholines / Q000032:analysis; D011247:Pregnancy; D012127:Respiratory Distress Syndrome, Newborn / Q000139:chemically induced / Q000209:etiology*; D013109:Sphingomyelins / Q000032:analysis
D010713:Phosphatidylcholines; D013109:Sphingomyelins; D007556:Isoxsuprine